91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

跳到内容

语言

切换导航

我的购物车

搜索

菜单

账号

设置

语言

首页
应用
蛋白质生物学
流式细胞术
Adalimumab (anti-TNF-alpha)

Adalimumab (anti-TNF-alpha)

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

种属反应性: Cynomolgus,Human,Mouse?,Rhesus Macaque
亚型: Human IgG1

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
A412002-1mg	1mg	期货
A412002-5mg	5mg	期货
A412002-10mg	10mg	期货

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Adalimumab (anti-TNF-alpha)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	TNFSF2/TNFa
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属	Cynomolgus,Human,Mouse?,Rhesus Macaque
偶联标记	Unconjugated

产品属性

抗体类型	Primary antibody
Format	Whole IgG
亚型	Human IgG1
轻链亚型	Kappa
SDS-PAGE	145.5 kDa
纯化方法	Protein A purified
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	331731-18-1

数据库链接

Wikipedia	Adalimumab
IMGT/mAb-DB	165
PubChem SID	178101561
PEP	adalimumab

关联配体

Ligand ID

4860

名称

adalimumab

别名

Humira®

类别

Antibody

学名

4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide

生物活性评价

The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).

评价

Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity . It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

X-ray structures of the apo and TNFα-bound Fab fragment of adalimumab have been deposited to the RCSB Protein Data Bank (IDs 4NYL and 3WD5 respectively).

Biosimilars:

Name	Trade name	Company	Clinical Phase	Indications
adalimumab-atto; ABP 501	Amjevita; Amgevita	Amgen	Approved (2016 FDA, 2017 EMA)	As per reference agent
adalimumab-adbm; BI 695501	Cyltezo	Boehringer Ingelheim	Approved (2017 FDA and EMA)	As per reference agent
ZRC-3197	Exemptia	Cadila Healthcare	Approved (2015 India)	Rheumatoid arthritis
adalimumab-bwwd; SB5	Hadlima	Samsung Bioepis	Approved (2019 FDA)	As per originator reference agent
adalimumab-aacf: MSB11022	Idacio; Kromeya	Fresenius Kabi	Approved (2019 EMA, 2022 FDA)	As per originator reference agent
BCD-057		Biocad	Ph 3 (NCT02762955)	Plaque psoriasis
adalimumab-adaz; GP2017	Hyrimoz; Hefiya; Halimatoz	Sandoz	Approved (2018 EMA and FDA)	As per originator reference agent
M923		Momenta Pharmaceuticals	Ph 3 (NCT02581345)	Plaque psoriasis, rheumatoid arthritis
adalimumab-fkjp; MYL-1401A; FKB327	Hulio	Mylan, Fujifilm Kyowa Kirin Biologics	Approved (2018 EMA, 2020 FDA)	As per originator reference agent
adalimumab-afzb; PF-06410293	Abrilada; Amsparity	Pfizer	Approved (2019 FDA, 2020 EMA)	As per originator reference agent
adalimumab; CT-P17	Yuflyma	Celltrion Healthcare Hungary Kft	Approved (EMA 2021)	As per originator reference agent
adalimumab-aqvh; CHS-1420	Yusimry	Coherus BioSciences	Approved (FDA 2021)	As per originator reference agent
IBI303		Innovent Biologics	Ph 3 (NCT02893254)	Active ankylosing spondylitis
AVT02	Hukyndra; Libmyris	Alvotech/DKSH/Stada Arzneimittel	Approved (EMA 2021)	As per originator reference agent

单字母多肽序列

三字母多肽序列

翻译后修饰

化学修饰

参考文献

1. Kempeni J. (1999) Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.. Ann Rheum Dis, 58 Suppl 1 (13): (I70-2). [PMID:10577977]
2. Wollheim FA. (2002) TNF inhibition as therapy for rheumatoid arthritis.. Expert Opin Investig Drugs, 11 (7): (947-53). [PMID:12084005]
3. Rau R. (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.. Ann Rheum Dis, 61 Suppl 2 (13): (ii70-3). [PMID:12379628]
4. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D et al.. (2016) Adalimumab in Patients with Active Noninfectious Uveitis.. N Engl J Med, 375 (10): (932-43). [PMID:27602665]
5. Kawalec P, Mikrut A, Wi?niewska N, Pilc A. (2013) Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis.. Arch Med Sci, 9 (5): (765-779). [PMID:24273556]
6. Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, Warrington S, Boyce M. (2017) Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.. Br J Clin Pharmacol, 83 (7): (1405-1415). [PMID:28133772]
7. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G et al.. (2016) A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.. Int J Rheum Dis, 19 (11): (1157-1168). [PMID:26176644]
8. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. (2017) Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.. Br J Dermatol, 177 (6): (1562-1574). [PMID:28755394]
9. Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A. (2018) Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.. Expert Opin Biol Ther, 18 (8): (921-930). [PMID:29962245]
10. Schreiber S, Yamamoto K, Muniz R, Iwura T. (2020) Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.. Pharmacol Res Perspect, 8 (3): (e00604). [PMID:32500668]